Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069809 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Phase 2 study, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT01069809 is a Phase 2 study that has completed, run by Argos Therapeutics. The registered enrollment target is 53 participants.
The verdict
NCT01069809, a Phase 2 study, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AGS-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069809
The ClinicalTrials.gov registry entry for NCT01069809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01069809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069809 about?
NCT01069809 is a clinical study titled "Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption". The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
What is the current status of trial NCT01069809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2010-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01069809?
The interventions under investigation include: Placebo (BIOLOGICAL), AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01069809?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.